Research Library › GHRH & Ghrelin-Receptor
CJC-1295 is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions and an added lysine carrying a Drug Affinity Complex (DAC) that binds blood albumin. It was developed by ConjuChem of Montreal, Canada, and described in 2005. The same modified 29-residue peptide without the DAC is sold as “CJC-1295 no DAC” or Modified GRF (1-29). Neither form is approved in any country as of 22 Oct 2026.
Key facts
| Type | Synthetic GHRH(1-29) analog; with DAC: 30 residues plus an albumin-binding linker |
|---|---|
| Derived from | Human GHRH, residues 1–29, with four substitutions |
| First described | 2005, ConjuChem Inc. (Jetté et al., Endocrinology) |
| Developed by | ConjuChem Inc., Montreal, Canada |
| Designed target | GHRH receptors on the anterior pituitary |
| Regulatory status (Oct 2026) | Not approved anywhere; FDA compounding nomination withdrawn; named on WADA 2026 list (S2) |
Who developed it
CJC-1295 was created at ConjuChem, a biotechnology company in Montreal, Canada. Its scientists published the design in 2005, identifying CJC-1295 as the lead long-lasting compound in a series of GRF(1-29) conjugates [1]. The 2006 study in healthy adults lists Sam Teichman as first author, with endocrinologist Lawrence Frohman among the co-authors [2].
What it was designed to target
The peptide is based on GRF(1-29), the shortest active portion of natural GHRH and the same sequence as sermorelin. ConjuChem replaced four of its amino acids and added an extra lysine at the end of the chain. That lysine carries the DAC, a reactive chemical linker designed to bond to a single site on serum albumin, the cysteine at position 34 (Cys34). In rat studies, the conjugate was detected bound to albumin within 15 minutes [1].
Like natural GHRH, CJC-1295 is designed to bind GHRH receptors on the anterior pituitary [1][2]. Tethering to albumin was intended to extend its half-life in circulation; the 2006 human study reported a half-life of roughly 6 to 8 days [2].
With DAC vs. no DAC (Modified GRF 1-29)
Two related peptides share the CJC-1295 name. CJC-1295 with DAC is the compound ConjuChem published: the substituted 29-residue backbone plus the lysine-linked DAC that binds albumin [1]. CJC-1295 without DAC, also called Modified GRF (1-29) or Mod GRF 1-29, is the same substituted 29-residue peptide with no albumin-binding linker.
The difference is the linker, not the receptor target. Without albumin binding, the no-DAC peptide is expected to clear from circulation far faster, in line with other short GRF(1-29) analogs. Published ConjuChem research covers the DAC form; “no DAC” is a later naming convention rather than a separately developed drug candidate.
Why it was created
ConjuChem’s platform aimed to extend the short half-life of therapeutic peptides by attaching them to albumin, the most abundant protein in blood [1]. CJC-1295 entered a phase 2 trial in a research program on HIV-associated visceral obesity [3][4].
Research timeline
- 2005: ConjuChem publishes the albumin-binding design and names CJC-1295 [1].
- 2005: A European phase 2 trial in adults with HIV is authorized [3].
- 2006: The first study in healthy adults is published [2].
- Jul 2006: ConjuChem halts its 192-patient phase 2 trial after a participant in Argentina dies; the company says it is too early to determine whether the drug was the cause [4][5].
Regulatory status as of October 2026
As of 22 Oct 2026, CJC-1295 is not approved in any country we identified. FDA lists it among withdrawn compounding nominations in its safety-risk table, citing serious adverse events such as increased heart rate [6]. It was not among the 12 peptides FDA moved off its Category 2 list in April 2026 [7]. The EU clinical trials register records the HIV trial as prematurely ended [3].
CJC-1295 is covered by the 2026 World Anti-Doping Agency Prohibited List under S2 as a GHRH analog, prohibited at all times [8].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
What is the difference between CJC-1295 with DAC and without DAC?
Both share the same modified 29-amino-acid GHRH backbone. The DAC version adds a lysine-linked chemical group that binds blood albumin to lengthen its half-life; the no-DAC version, also called Mod GRF 1-29, lacks that linker.
Who developed CJC-1295?
CJC-1295 was developed by ConjuChem Inc. in Montreal, Canada, and first described in the journal Endocrinology in 2005.
Is CJC-1295 FDA approved?
No. As of 22 Oct 2026 CJC-1295 is not approved in the U.S. or anywhere else, and its FDA compounding nomination was withdrawn.
What does DAC stand for?
DAC stands for Drug Affinity Complex, ConjuChem’s chemical linker designed to bond a peptide to the Cys34 site on serum albumin.
Why was the CJC-1295 trial stopped?
In July 2006 ConjuChem halted its phase 2 HIV trial after a participant died; the company said it was too early to know whether the drug was the cause.
Sources
- Jetté L, Léger R, Thibaudeau K, et al. (ConjuChem Inc., Montreal). Human growth hormone-releasing factor (hGRF)1–29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. doi:10.1210/en.2004-1286. Link
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. doi:10.1210/jc.2005-1536. Link
- EU Clinical Trials Register. EudraCT 2005-003797-25: Randomized, placebo-controlled, double-blind phase 2 study of CJC-1295 given for 12 weeks in HIV-infected adults with HIV-associated visceral obesity (sponsor ConjuChem; status: prematurely ended). Link
- BioWorld. Patient death in ConjuChem phase II trial halts dosing. 17 Jul 2006. Link
- Bernard EJ. Lipodystrophy study halted after patient death. aidsmap, 31 Jul 2006. Link
- U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list), content current as of 22 Apr 2026. Link
- Faviero GF, Asebey EJ (Frier Levitt). FDA to remove 12 popular peptides from the Category 2 “do not compound” list. 16 Apr 2026. Link
- World Anti-Doping Agency. 2026 Prohibited List, S2.2.4 (GHRH and its analogues; growth hormone secretagogues; GH-releasing peptides). Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
